Optimizing Dermatology CoverMyMeds Integration for Specialty Drug PAs

Klivira's dermatology CoverMyMeds integration streamlines electronic prior authorization for critical specialty medications, ensuring faster patient access to treatment.

Dermatology practices face unique prior authorization challenges, particularly with high-cost biologics and specialty drugs for chronic conditions like psoriasis, atopic dermatitis, and hidradenitis suppurativa. Navigating the manual ePA process for these medications can lead to delays, increased administrative burden, and potential treatment interruptions. Klivira automates this workflow, connecting directly to CoverMyMeds to mitigate these operational bottlenecks.

The Critical Role of CoverMyMeds in Dermatology PA

Dermatology relies heavily on specialty drugs, often requiring pharmacy benefit prior authorizations. CoverMyMeds serves as a primary electronic channel for submitting these requests to Pharmacy Benefit Managers (PBMs) and health plans. Klivira’s integration with CoverMyMeds ensures that prescription-related PAs for biologics like Dupixent, Cosentyx, and Tremfya are submitted efficiently and accurately, reducing manual data entry and improving turnaround times.

Common Dermatology Medications Requiring ePA via CoverMyMeds

Biologics for psoriasis (e.g., adalimumab, secukinumab, guselkumab, risankizumab)
Biologics for atopic dermatitis (e.g., dupilumab, tralokinumab)
Biologics for hidradenitis suppurativa (e.g., adalimumab, secukinumab)
Oral targeted therapies (e.g., apremilast, deucravacitinib, JAK inhibitors)
Select specialty topical medications

Streamlining Documentation for Dermatology ePA Submissions

Accurate and complete clinical documentation is paramount for successful dermatology prior authorizations. Klivira's platform supports the aggregation of required data points, informed by AAD Clinical Guidelines and NCCN guidelines, directly from your EMR. This includes specific severity scores (PASI, EASI, BSA), documentation of prior topical or systemic therapy trials, and evidence of necessary pre-biologic screenings like TB and hepatitis. These data elements are then systematically prepared for submission through the CoverMyMeds channel.

Addressing Dermatology-Specific Denial Patterns in ePA

Common denial reasons in dermatology PA, such as non-compliance with step therapy protocols for psoriasis biologics or insufficient documentation of disease severity, can significantly delay patient care. Klivira's integration with CoverMyMeds helps proactively identify and address these issues by validating submission criteria against payer policies and clinical guidelines before submission. This reduces the incidence of denials and the need for time-consuming appeals.

Integrating Klivira with Your EMR for Seamless Dermatology Workflows

Automated extraction of patient demographics and clinical notes from EMRs
Electronic routing of pharmacy benefit PAs through CoverMyMeds via NCPDP SCRIPT
Real-time status updates pushed back to the EMR for enhanced visibility
Consolidated view of all PA statuses across various payer portals and ePA channels
Support for SMART on FHIR for standardized data exchange

Optimizing Chronic Biologic Re-authorization Cycles

Many dermatology patients require periodic re-authorization for chronic biologic treatments, typically on 6 or 12-month cycles. Klivira's system tracks these re-authorization timelines, automatically initiating the process and ensuring that updated clinical documentation is gathered and submitted through CoverMyMeds ahead of expiration. This proactive approach prevents gaps in treatment and maintains continuity of care for conditions like psoriasis and atopic dermatitis.

Frequently asked questions

How does Klivira handle the distinction between medical and pharmacy benefit PAs for dermatology biologics?

Klivira's platform intelligently routes prior authorization requests based on the specific drug and payer policy. For pharmacy benefit drugs, such as most self-injectable biologics, requests are channeled through ePA platforms like CoverMyMeds. For medical benefit drugs or procedures, Klivira uses X12 278 transactions or direct payer portal submissions, ensuring the correct channel is always utilized.

Can Klivira integrate with my EMR to pull dermatology-specific clinical data for CoverMyMeds submissions?

Yes, Klivira integrates with leading EMRs via SMART on FHIR and other protocols to extract relevant clinical data. This includes dermatology-specific documentation like PASI, EASI, and BSA scores, as well as records of prior therapies and diagnostic screenings, which are critical for building a complete prior authorization request for submission to CoverMyMeds.

How does Klivira help with step therapy requirements for dermatology biologics when using CoverMyMeds?

Klivira's system is configured with payer-specific step therapy logic, informed by clinical guidelines such as those from the AAD. Before submission through CoverMyMeds, the platform flags missing documentation for conventional therapies (e.g., topicals, phototherapy, methotrexate) or biosimilar considerations, guiding staff to provide the necessary information to meet payer requirements and reduce denials.

Does Klivira support re-authorizations for chronic dermatology conditions?

Absolutely. Klivira's platform includes robust re-authorization management capabilities. It tracks the expiration dates for existing prior authorizations for chronic dermatology biologics, proactively alerts staff, and facilitates the submission of updated clinical information through channels like CoverMyMeds to ensure continuous patient access to treatment.

What about Mohs surgery PAs, which are not typically handled by CoverMyMeds?

While CoverMyMeds primarily focuses on pharmacy benefit medications, Klivira's comprehensive platform also addresses medical benefit procedures like Mohs surgery. For Mohs, Klivira uses X12 278 or direct payer portal submissions, validating against AAD Appropriate Use Criteria and ensuring all required documentation (site, tumor type) is included for efficient processing.